Roivant's brepocitinib cuts steroid use in non-infectious uveitis in Phase 3 trials

Roivant Sciences and its subsidiary Priovant reported that their TYK2/JAK inhibitor brepocitinib met all primary and secondary endpoints in two identical Phase 3 studies (Clarity‑1 and Clarity‑2) in patients with non‑infectious uveitis. The drug significantly lowered the need for steroid therapy, a key goal in managing the eye disease.

Analysts highlighted the results as a "clean win" and noted that brepocitinib appeared more effective than AbbVie’s Humira, the only approved non‑steroid treatment for this condition. The commentary suggests the candidate could become a preferred option for clinicians.

Brepocitinib was previously approved in August for the autoimmune skin disease dermatomyositis under the brand name Lisraya. Roivant licensed the molecule from Pfizer when it spun off Priovant in 2022 and is now pursuing regulatory approval for the new eye‑disease indication.